• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ATORVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • ATORVASTATIN chembl:CHEMBL1487 Approved

    Alternate Names:

    ATORVASTATIN
    ZARATOR
    TAHOR
    PREVENCOR
    SORTIS
    CARDYL
    LIPITOR
    LCF872
    (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
    chembl:CHEMBL1487
    drugbank:01076
    pubchem.compound:60823
    rxcui:83367
    chemidplus:134523-00-5

    Drug Info:

    Drug Indications anticholesterolaemic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypecholesterolemic agent
    Year of Approval 1996
    Drug Class anticholesteremic agents
    Drug Categories heptanoic acids
    Drug Categories agents causing muscle toxicity
    Drug Categories bsep/abcb11 substrates
    Drug Categories cytochrome p-450 cyp2b6 inducers (strength unknown)
    Drug Categories cytochrome p-450 cyp2c19 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c8 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c9 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 cyp3a7 substrates
    Drug Categories cytochrome p-450 enzyme inducers
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories hypolipidemic agents indicated for hyperlipidemia
    Drug Categories lipid modifying agents, plain
    Drug Categories oatp1b1/slco1b1 inhibitors
    Drug Categories oatp1b3 substrates
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories ugt1a1 substrates
    Drug Categories ugt1a3 substrates
    (4 More Sources)

    Publications:

    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Baxter et al., Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight., Trends Endocrinol. Metab.
    Maejima et al., 2004, Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell., Biochem. Biophys. Res. Commun.
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Thompson JF et al., 2009, Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort., Circ Cardiovasc Genet
    Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
    Jafari et al., 2003, Efficacy of alternate-day dosing versus daily dosing of atorvastatin., J. Cardiovasc. Pharmacol. Ther.
    Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
    Cuevas A et al., 2016, HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals., Basic Clin Pharmacol Toxicol
    Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
    Bösel et al., 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones., J. Neurochem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Wassmann et al., 2001, Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase., Mol. Pharmacol.
    Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics
    Kajinami K et al., 2004, Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin., Atherosclerosis
    Srivastava A et al., 2010, Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy., Dis Markers
    Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol
    Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol
    Iakoubova OA et al., 2008, Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study., J Am Coll Cardiol
    Iakoubova OA et al., 2010, KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study., Eur J Cardiovasc Prev Rehabil
    Ruiz-Iruela C et al., 2018, KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment., PLoS One
    Xu et al., 2002, Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin., Biochem. Pharmacol.
    Planavila et al., 2005, Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells., Biochim. Biophys. Acta
    Zineh et al., 2006, Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study., Pharmacotherapy
    Puccetti L et al., 2010, Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study., Atherosclerosis
    Korhonova M et al., 2015, Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes., PLoS One
    Chauvin et al., 2013, Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors., Clin Pharmacokinet
    Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.
    Oria de Suárez et al., 2006, [Effect of atorvastatin on Fas (CD95/Apo-1) expression in normal or ischemic brain]., An Med Interna
    Ortego et al., 1999, Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells., Atherosclerosis
    Pérez-Castrillón JL et al., 2008, Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome., Ann Nutr Metab
    Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
    Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
    Gao Y et al., 2008, CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin., Eur J Clin Pharmacol
    Burton et al., 2007, Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient., Ann Pharmacother
    Becker ML et al., 2010, Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy., Pharmacoepidemiol Drug Saf
    Becker ML et al., 2013, Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy., Pharmacogenomics J
    Prado Y et al., 2018, Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin., Basic Clin Pharmacol Toxicol
    Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
    Soehnlein et al., 2004, Atorvastatin induces tissue transglutaminase in human endothelial cells., Biochem. Biophys. Res. Commun.
    Arazi SS et al., 2008, Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response., Clin Chim Acta
    Suh JW et al., 2014, Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial., J Atheroscler Thromb
    Wilke RA et al., 2005, Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage., Pharmacogenet Genomics
    Willrich MA et al., 2008, CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia., Clin Chim Acta
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
    Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
    Drogari E et al., 2014, POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia., Pharmacogenomics
    Pérez-Castrillón JL et al., 2014, Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin., Rheumatol Int
    Olmos JM et al., 2012, Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates., Pharmacogenomics J
    Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.
    Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
    Frudakis TN et al., 2007, CYP2D6*4 polymorphism is associated with statin-induced muscle effects., Pharmacogenet Genomics
    Dobreanu et al., 2007, Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin., Rom J Intern Med
    Bartok et al., 2005, Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor., Thromb. Res.
    Santos PC et al., 2014, The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia., Pharmacogenet Genomics
    Pérez-Castrillón JL et al., 2009, Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene., Endocr J
    Osman et al., 2006, Role of human valve interstitial cells in valve calcification and their response to atorvastatin., Circulation
    Urbich et al., 2005, FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells., FASEB J.
    Keskitalo JE et al., 2009, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin., Clin Pharmacol Ther
    Goebel et al., 2005, Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain., J. Investig. Med.
    Berk-Planken et al., 2003, Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant., Diabetes Care
    Mega JL et al., 2009, Identification of genetic variants associated with response to statin therapy., Arterioscler Thromb Vasc Biol
    Goicoechea et al., 2006, Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease., J. Am. Soc. Nephrol.
    Kadam P et al., 2016, Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population., J Clin Pharm Ther
    Wei KK et al., 2011, Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin., J Clin Pharm Ther
    Hoenig MR et al., 2011, The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort., J Clin Lipidol
    Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
    Keskitalo JE et al., 2008, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin., Clin Pharmacol Ther
    Rebecchi IM et al., 2009, ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment., Biochem Pharmacol
    Fu R et al., 2008, Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
    Himbergen TM et al., 2005, The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia., J Intern Med
    Nagila A et al., 2009, Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status., Pharmacol Rep
    Ghayour-Mobarhan et al., Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study., Angiology
    van Venrooij FV et al., 2003, Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes., Diabetes Care
    Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
    Cerda A et al., 2010, Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin., Clin Chim Acta
    Raal et al., 2003, Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia., Atherosclerosis
    Birnbaum et al., 2005, Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury., Cardiovasc. Res.
    Hubacek JA et al., 2015, Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population., Eur J Intern Med
    Lau et al., 2007, effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers., Clin. Pharmacol. Ther.
    Potaczek DP et al., 2005, The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease., Thromb Haemost
    Pal et al., 2002, Cholesterol esters regulate apoB48 secretion in CaCo2 cells., Atherosclerosis
    Forster et al., 2002, Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates., Atherosclerosis
    Mohammadi et al., 1998, Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells., Arterioscler. Thromb. Vasc. Biol.
    Miltiadous et al., 2005, Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia., Pharmacogenet. Genomics
    Wilcox et al., 1999, Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin., J. Lipid Res.
    Telford et al., 2003, Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB., J. Lipid Res.
    Burnett et al., 1999, The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs., Endocrinology
    Tsimikas et al., 2004, High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial., Circulation
    Chan et al., 2002, Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia., Diabetes
    Taldone et al., 2008, Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin., Bioorg. Med. Chem. Lett.
    García-García AB et al., 2005, Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia., Pharmacogenet Genomics
    Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.
    Režen T et al., 2017, Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor <i>α</i> Complex., Drug Metab Dispos
  • ATORVASTATIN   CYP7A1

    Interaction Score: 4.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 15262185 26932749 21128988


    Sources:
    PharmGKB

  • ATORVASTATIN   ABCG8

    Interaction Score: 3.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 15262185 20592455


    Sources:
    PharmGKB

  • ATORVASTATIN   MYLIP

    Interaction Score: 1.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25171759


    Sources:
    PharmGKB

  • ATORVASTATIN   KIF6

    Interaction Score: 1.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20403483 18222353 18222355 20215968 30304062


    Sources:
    PharmGKB

  • ATORVASTATIN   SCAP

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18435918


    Sources:
    PharmGKB

  • ATORVASTATIN   COQ2

    Interaction Score: 0.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20347093


    Sources:
    PharmGKB

  • ATORVASTATIN   HMGCR

    Interaction Score: 0.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase
    Specific Action of the Ligand Competitive
    Endogenous Drug? False

    PMIDs:
    17563401 15109613 15474503 18815589 18332269 16103896 20031582 18261733 12808485 15199031 26408409 12769127 15748157 11752352


    Sources:
    TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • ATORVASTATIN   LEPR

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19023160


    Sources:
    PharmGKB

  • ATORVASTATIN   APOB

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11882317 12119202 9598838 15864114 10357840 12562847 10537160 15353498 12145148


    Sources:
    NCI

  • ATORVASTATIN   SCARB1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20064494


    Sources:
    PharmGKB

  • ATORVASTATIN   HSPD1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15678257


    Sources:
    NCI

  • ATORVASTATIN   APOA5

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19530961


    Sources:
    PharmGKB

  • ATORVASTATIN   PON1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18430057 16238680 19904013


    Sources:
    PharmGKB

  • ATORVASTATIN   CETP

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 12663600 15856070


    Sources:
    PharmGKB

  • ATORVASTATIN   SOAT1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14644397


    Sources:
    NCI

  • ATORVASTATIN   LIPC

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12547874


    Sources:
    NCI

  • ATORVASTATIN   APOE

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 19667110 20031582 17289397


    Sources:
    PharmGKB

  • ATORVASTATIN   RYR2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692 25753936


    Sources:
    PharmGKB

  • ATORVASTATIN   ABCA1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20031551


    Sources:
    PharmGKB

  • ATORVASTATIN   MTTP

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15864113


    Sources:
    PharmGKB

  • ATORVASTATIN   ITGAM

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18333374


    Sources:
    NCI

  • ATORVASTATIN   PLAT

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17130267


    Sources:
    NCI

  • ATORVASTATIN   TFPI

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15792677


    Sources:
    NCI

  • ATORVASTATIN   POR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25521355


    Sources:
    PharmGKB

  • ATORVASTATIN   CD40LG

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17064201


    Sources:
    NCI

  • ATORVASTATIN   CXCL10

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10559511


    Sources:
    NCI

  • ATORVASTATIN   FDPS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24311107 21151198


    Sources:
    PharmGKB

  • ATORVASTATIN   UGT1A3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22555810


    Sources:
    PharmGKB

  • ATORVASTATIN   HTR3B

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • ATORVASTATIN   FAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16796407


    Sources:
    NCI

  • ATORVASTATIN   FGF2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12147302


    Sources:
    NCI

  • ATORVASTATIN   TGM2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15313180


    Sources:
    NCI

  • ATORVASTATIN   BDKRB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   NR1I3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    28536098


    Sources:
    DrugBank

  • ATORVASTATIN   BGLAP

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16820635


    Sources:
    NCI

  • ATORVASTATIN   IL2RA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16207471


    Sources:
    NCI

  • ATORVASTATIN   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 15900215 18727922 18695978 17289397 15284534


    Sources:
    PharmGKB

  • ATORVASTATIN   HLA-DRB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692


    Sources:
    PharmGKB

  • ATORVASTATIN   AGTR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11179461


    Sources:
    NCI PharmGKB

  • ATORVASTATIN   ABCC2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22186618 29178257


    Sources:
    PharmGKB

  • ATORVASTATIN   AHR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    26366873 23703578 17327465


    Sources:
    DrugBank

  • ATORVASTATIN   UGT2B7

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   LDLR

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   MAPK10

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16701707


    Sources:
    NCI

  • ATORVASTATIN   SLCO2B1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   HDAC2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • ATORVASTATIN   SLCO1B3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   SLCO1B1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17192770


    Sources:
    NCI

  • ATORVASTATIN   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16103896 21392722 15616150 26932749 19802823 19238649 18851956


    Sources:
    NCI PharmGKB

  • ATORVASTATIN   DPP4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18068977


    Sources:
    DrugBank

  • ATORVASTATIN   CYP2C8

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   NOS1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15639473


    Sources:
    NCI

  • ATORVASTATIN   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19474787


    Sources:
    PharmGKB

  • ATORVASTATIN   HTR7

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17600820


    Sources:
    PharmGKB

  • ATORVASTATIN   ACE

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16116691


    Sources:
    PharmGKB

  • ATORVASTATIN   UGT1A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18997459


    Sources:
    PharmGKB

  • ATORVASTATIN   PIK3CG

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15824087


    Sources:
    NCI

  • ATORVASTATIN   PPARD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16139565


    Sources:
    NCI

  • ATORVASTATIN   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18528690 17200431 19802823


    Sources:
    NCI PharmGKB

  • ATORVASTATIN   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24140730


    Sources:
    PharmGKB

  • ATORVASTATIN   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17700359


    Sources:
    PharmGKB

  • ATORVASTATIN   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DrugBank: DB01076

    • Version: 5.1.7

    Alternate Names:
    Lipotropic Drug Brand
    Liprimar Drug Brand
    Liptruzet Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories agents causing muscle toxicity

    Publications:
    Korhonova M et al., 2015, Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes., PLoS One
    Chauvin et al., 2013, Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors., Clin Pharmacokinet
    Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.

  • TEND: ATORVASTATIN

    • Version: 01-August-2011

    Alternate Names:
    ATORVASTATIN Primary Drug Name

    Drug Info:
    Drug Class anticholesteremic agents
    Year of Approval 1996

    Publications:

  • TdgClinicalTrial: ATORVASTATIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypecholesterolemic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: ATORVASTATIN

    • Version: 14-September-2017

    Alternate Names:
    C28837 NCI drug code

    Drug Info:

    Publications:
    Planavila et al., 2005, Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells., Biochim. Biophys. Acta
    Soehnlein et al., 2004, Atorvastatin induces tissue transglutaminase in human endothelial cells., Biochem. Biophys. Res. Commun.
    Wassmann et al., 2001, Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase., Mol. Pharmacol.

  • PharmGKB: atorvastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Kajinami K et al., 2004, Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin., Atherosclerosis

  • GuideToPharmacology: 135649972

    • Version: 29-September-2020

    Alternate Names:
    ATORVASTATIN GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Atorvastatin

    • Version: 2020.06.01

    Alternate Names:
    D01QIN TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1487

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21